Hemab Therapeutics Holdings Common Stock P/E Ratio

The latest P/E ratio for COAG is -37.42. That is below the Healthcare sector average of 22.57. Investors often review this figure alongside Hemab Therapeutics Holdings Common Stock's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, COAG currently prints -37.42 for P/E ratio, while the sector average sits near 22.57. That is roughly 265.8% below the sector mean. Large gaps often invite a closer look at Hemab Therapeutics Holdings Common Stock's growth, margins, and balance sheet.

A P/E ratio of -37.42 for Hemab Therapeutics Holdings Common Stock is not 'good' or 'bad' on its own. Compare it with the peer average (22.57) and with COAG's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting COAG's P/E ratio (-37.42), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Hemab Therapeutics Holdings Common Stock's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.